Royalty Pharma Raises Full Year 2023 Guidance
March 15, 2023 08:00 ET
|
Royalty Pharma plc
Royalty Pharma now expects 2023 Adjusted Cash Receipts(1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 ...
Royalty Pharma Appoints Ashwin Pai as Executive Vice President, Investments
March 01, 2023 08:15 ET
|
Royalty Pharma plc
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty...
Royalty Pharma Reports Q4 and Full Year 2022 Results
February 15, 2023 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts(1) (non-GAAP) of $1,064 million in Q4 2022Announced transactions of up to $3.5 billion in 2022, including...
Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February...
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 18, 2023 08:25 ET
|
Royalty Pharma plc
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15,...
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023 09:25 ET
|
Royalty Pharma plc
2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be approximately $2,785...
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023 09:15 ET
|
Royalty Pharma plc
Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500...
Royalty Pharma Announces Dividend Increase
January 09, 2023 08:30 ET
|
Royalty Pharma plc
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
January 04, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at...
Royalty Pharma Announces Expansion of Senior Leadership Team
December 15, 2022 08:15 ET
|
Royalty Pharma plc
Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior...